Drug Profile
Bevacizumab biosimilar - Kashiv BioSciences
Latest Information Update: 12 Jan 2022
Price :
$50
*
At a glance
- Originator Therapeutic Proteins International
- Class Antineoplastics; Eye disorder therapies; Immunotherapies; Monoclonal antibodies
- Mechanism of Action Angiogenesis inhibitors; Vascular endothelial growth factor A inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 03 Jan 2019 Kashiv Pharma acquired all the assets of Adello Biologics and changed its name to Kashiv BioSciences
- 16 Nov 2016 Therapeutic Proteins International is now called Adello Biologics
- 24 Jun 2015 Discontinued for Cancer in USA (unspecified route)